The incidence of esophageal adenocarcinoma has risen substantially over the past few years, and now surpasses the incidence of esophageal squamous cell carcinoma in Western countries. This rise is unparalleled and can only be explained by the rising incidence of Barretts esophagus�a direct consequence of abnormal gastroesophageal reflux�in Western countries. Dr. Prateek Sharma, in this symposium, addresses die epidemiology and pathogenesis of cancer
of the esophagogastric junction and emphasizes this rapid increase that we have observed. Dr. Jeffrey Peters characterizes the uniqueness of esophageal adenocarcinoma and the changes observed in the presentation and management of this tumor. Dr. Lee Swanstrom addresses the use of minimally invasive therapies to treat esophageal adenocarcinoma. Finally, Dr. Kenneth Wang discusses the multiple elements that we have today to treat esophageal adenocarcinoma.